Humana (HUM)
(Delayed Data from NYSE)
$260.71 USD
+2.88 (1.12%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $260.81 +0.10 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$260.71 USD
+2.88 (1.12%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $260.81 +0.10 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will Lower CenterWell Profit Hurt Humana's (HUM) Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Select Medical (SEM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Select Medical (SEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Humana (HUM) concluded the recent trading session at $515.48, signifying a -1.09% move from its prior day's close.
Humana (HUM) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Humana (HUM) settling at $519.87, representing a -0.83% change from its previous close.
Why Humana (HUM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Company News for Oct 12, 2023
by Zacks Equity Research
Companies in The News Are: AZZ,XOM,PXD,PLUG,HUM
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Humana (HUM) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana (HUM) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Humana (HUM) concluded the recent trading session at $501.54, signifying a +0.68% move from its prior day's close.
Humana (HUM) Boosts Healthcare Choices for MA Members in Denver
by Zacks Equity Research
Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.
Here's Why Investors Should Retain Humana (HUM) Stock Now
by Zacks Equity Research
Humana (HUM) benefits from an upgraded health plan offering suite, expanding Medicare Advantage membership and solid cash reserves.
Cigna (CI) Unveils 2024 Expansion Plans, Eyes Membership Growth
by Zacks Equity Research
Cigna (CI) declares the availability of a varied set of health plans across new counties in 2024. It, thereby, places intensified focus on growing its Medicare business.
Humana's (HUM) 2024 MA Plans Promise a Wider Set of Benefits
by Zacks Equity Research
Humana (HUM) aims to expand the reach of its Medicare plans across newer U.S. counties in 2024 through integrating multiple lucrative benefits within them.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $491.74, marking a +1.07% move from the previous day.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $501.07, moving +1.42% from the previous trading session.
Humana (HUM) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $473.80, marking a -0.05% move from the previous day.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $472.50 in the latest trading session, marking a +0.73% move from the prior day.
The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group
by Zacks Equity Research
Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group are part of the Zacks top Analyst Blog.
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $471.98, marking a +1.49% move from the previous day.
Top Analyst Reports for Humana, Cintas & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Humana Inc. (HUM), Cintas Corporation (CTAS) and Biogen Inc. (BIIB).
Humana (HUM) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Hold Humana (HUM) in Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.